ELRIG Drug Discovery 2026
14 October 2026 – 15 October 2026
ExCeL London, London, United Kingdom
ELRIG's Drug Discovery 2026 is a free-to-attend drug discovery and life sciences conference and exhibition held at ExCeL London, marking 20 years of the event. Scientific tracks cover next-generation biophysics, cell-based models, AI and experimental design, radioligands and bioconjugates, CRISPR/Cas technologies, multi-omics, imaging, microbes to medicines and AI in medicinal chemistry, alongside keynote sessions, a Breakthrough Zone for start-ups, a Learning Zone for early career professionals, posters and an exhibition hall.
157 sessions · 136 speakers
Organiser (1)
Media Partners (2)
Sponsors (10)
Hamilton · Pfizer · Revvity · Capgemini · WuXi AppTec · Cenevo · AstraZeneca · GSK · Instem · Promega
Exhibitors (34)
Thermo Fisher · Cell Signaling Technology · Hamilton · Ppmld Ltd · Klarbio · Revvity · Lightcast · Royal Society of Chemistry · Pelago Bioscience · Samplix ApS · Sighthound Life Science Consulting · Automata · WuXi AppTec · Selvita · HORIBA · Cytiva · Cenevo · Cellvanta Ltd · Salopian Scientific Ltd · AstraZeneca · Codon Communications · Innoprot · Bionow · University of Exeter · Bruker Luxendo GmbH · CPI · Gilson · GSK · Bioicus Lab · Mitsui Chemicals Europe GmbH · Instem · CAS · Promega · Atomixel
Knowledge Partner (1)
Supporting Partners (3)
MICE Concierge Ltd. · AstraZeneca · GSK
Speakers (136)
- Antoine Espinet CEO, Mfx
- Melanie Leveridge Vp Assays, Profiling & Cell Sciences, Astrazeneca
- Zahra Jawad CEO & Founder, Creasallis Ltd
- Ane Ogbe Associate Scientific Director, Moderna
- Alexandra Sevko Consultant, Translational Research, Resilient Collective
- Mrs Helen Harrison Director of Biology, AQEMIA
- Chris Ugbode Science Portfolio Manager, UK Dementia Research Institute
- Joris Langlois Customer Success Specialist, CAS
- Goran Dahl Associate Principal Scientist, Biophysics, AstraZeneca
- Raghib Ali CEO, Our Future Health
- Justin Melnick Director - Life Sciences, Capgemini
- Sam Barrell CEO, LifeArc
- A Ganesan Professor, IUPAC
- Amro Ahmed-Ebbiary Principal Scientist, GSK
- Augustin Amour Biology Head, Amour Scientific Consulting
- Blessing Airhihen Senior Lecturer In Pharmacology, Nottingham Trent University
- Christopher Cooper Senior Lecturer, University of Huddersfield/Surrey
- Farah Patell-Socha Chief Business Officer, Amilon Bio
- Grace Thoburn Executive Editor, Royal Society Of Chemistry
- Hitesh Sanganee Director, Future Bio Consutling
- Jarrod Walsh Director - Affinity Screening, Astrazeneca
- Jerry Reen Senior Lecturer And Principal Investigator, University College Cork
- Madhurima Dey Senior Research Investigator, Isomorphic Labs
- Magdalena Otrocka Lead Molecular Biologist, Ardigen
- Manuela Beil-Peter Europe Ambassador, SLAS
- Markus Gershater Ceo and Cofounder, Synthace
- Martin Swarbrick Senior Director, Pharmaron
- Ming Jiang Deputy Head Of Screening and Automated Science, The Francis Crick Institution
- Nadine Myers Senior Scientist I, Assay Biology, Domainex
- Nick Tribble Head Of Antibody Discovery & Protein Sciences, Cancer Research Horizons
- Rajarshi Banerjee Consultant Physician, Independent
- Sonia Houghton Director, Sonia Houghton Consulting Ltd
- Sophia Amenyah Assistant Professor, Northumbria University
- Stuart Haynes Group Leader, Cancer Reseach Horizons
- Ulrike Künzel Associate Principal Scientist, Astrazeneca
- Alan Parker Professor Of Translational Virology, Cardiff University
- Alan Parkin VP Product, Cenevo -
- Alexander Kingdon Post-doctoral Research Associate, Liverpool School Of Tropical Medicine
- Ali Jazayeri Operating Partner, SV Health Investors
- Alonso Haysom-Rodriguez Research Scientist, Medicinal Chemistry, Bicycle Therapeutics
- Aman Mebrahtu Post Doctoral Research Associate, Imperial College London
- Ana Amélia Sanchez Iacia Bioassay Technical Development Specialist, CNPEM
- Ana-Maria Florescu Director, Head Of Computational Biology, Molecular Partners AG
- Andrea Gamir Morralla Principal Scientist, GSK
- Andrew Bassett Head Of Cellular And Gene Editing Research, Wellcome Sanger Institute
- Andy Merritt Head Of Academic Engagement, LifeArc
- Anna Veprik Senior Clinical Project And Alliance Manager, Perspectum
- Anne Phelan SVP, Target Discovery, GlaxoSmithKline
- Antigoni Gogolou Research Associate, Milner Therapeutics Institute, University Of Cambridge
- Antonio Serrano Senior Product Manager, Revvity
- Argyris Politis Professor, University of Manchester
- Balakumar Vijayakrishnan Director Of Bioconjugation and Analytical, Astrazeneca
- Ben Dugan Scientist, Astrazeneca
- Bhuvaneish Selvaraj Senior Research Fellow, Uk Dri, University Of Edinburgh
- Bin Liu Scientific Director, WuXi AppTec
- Bishara Marzook Postdoc/Incoming Group Leader, The Francis Crick Institute/Gulbenkian Institute of Molecular Medicine
- Brinton Seashore-Ludlow Senior Researcher, Karolinska Institute
- Can Zhao Reader In Translational Microbiology, Manchester Metropolitan Unversity
- Carmen Herranz Ors Principal Bioinformatician, Wellcome Sanger Institute
- Christian Parker Associate Professor, Novartis
- Christos Georgiadis Senior Research Fellow, UCL, GOS Institute Of Child Health
- Chun-Wa Chung Head/ Executive Director Structure & Biophysical Sciences, Gsk
- Daniel Bedinger Director Of Application Science, Carterra
- Danielle Harper Postdoc, Swansea University
- Darren Cawkill Vice President, Apollo Therapeutics Ltd
- Del Trezise Chair, Elrig
- Dhaliwal Kev Professor, University Of Edinburgh
- Di Smith Scientist, GSK
- Elnaz Gozalpour DMPK-Associate Director, Pharmaron
- Emma King-Smith Chancellor's Fellow, University Of Edinburgh
- Emmanouil Metzakopian CEO, Cellcodex
- Fernanda Ricci Head Advanced Cellular Assays, Axxam S.p.A
- Fiona Jeganathan Head Of Screening And Pharmacology, ARUK UCL DDI
- Gordon Dougan President, Microbiology Society
- Gosia Wamil Consultant Cardiologist, Deep Medicine, University Of Oxford
- Guido Cimoli Sales Development Manager, Tecan
- Hannah Mizen Associate Principal Scientist, Camgene Therapeutics
- Heather Ramsay Strategic Development & Enterprise Lead, NIHR BioResource
- Ian Wall Head, Molecular Design, GSK
- Idi Liko Head Of Ms, EIT
- Jacqueline Fok Investment Director, Softbank Investment Advisers
- Jana Voigt Director, Cam Innovations
- Jason Mellad Ceo, Otoimmune
- Jason Shields Associate Principal Scientist, AstraZeneca
- Johanna Perens CTO & Co-founder, Vibraint Aps
- Jordan Lane CSO & Co-founder, Ignota Labs
- Joshua Schwochert CSO And Co-founder, Unnatural Products
- Juergen Loskutov Business Title Scientific Leader, Bio Bank, GSK
- Juhi Sardana Associate Director, AstraZeneca
- Justyna Mysliwy Executive Director, Research, Iksuda Therapeutics
- Kärt Tomberg Ceo And Co-founder, Expressionedits
- Kelly Hunter Chief Scientific Officer, Propath Uk
- Laura Eghobamien Independent Scientific consultant, Black Medical Scientific Network
- Laura Parton VP, R&D Project & Portfolio Strategy, Charm Therapeutics
- Layla Hosseini-Gerami Co-founder, Chief Data Science Officer, Ignota Labs
- Léa Wenger Ceo And Co-founder, Cyclana Bio
- Liana Bauer Phd Student, Karlsruhe Institute of Technology
- Linda Oyama Senior Lecturer In Microbiomics, Amr & One Health, Queen's University Belfast
- Loukik Arora Investment Lead, Macmillan Cancer Support (macmillan Ventures)
- Lovely Paul Solomon Devakumar Senior Scientist, Functional Genomics Centre
- Lucia Banci Professor, Cerm - University Of Florence
- Manuel Pinto Principal Scientist, Avacta Therapeutics
- Marcello Maresca Senior Director, PhD
- Maria Beatrice Panico Chief Medical Officer, Scendea
- Mark Charles Associate Director, Nxera
- Matthew Coghlan Vice President, Eli Lilly And Company
- Menelas Pangalos Venture Partner, Omega Funds
- Millie Tyler Senior Scientist, AstraZeneca
- Natasha Fothergill-Misbah Senior Research Associate, Newcastle University
- Nathasia Muwanigwa Research Fellow, University College London
- Oliver Carney Applications Manager, BMG LABTECH
- Olivier Frey VP Technology, InSphero AG
- Olubunmi Martindale-Sheldon Director, Histopathology Lab Operations, UK, Diagnexia UK Limited
- Owen Davis Principal Scientist - Medicinal Chemistry, Artios Pharma
- Pablo F”. Cespedes Principal Investigator, University Of Oxford
- Paresh Malhotra Professor of Clinical Neurology, Imperial College/UK Dementia Research Institute
- Paul Leeson Director, Paul Leeson Consulting Ltd
- Pierre Socha Partner, Amadeus Capital Partners
- Regine Anderson Senior Scientist - Biological Samples, MDC
- Remon Van Geel Director Biochemistry, Lonza
- Roger Clark Director, Hit Id + Profiling, Charles River Labs
- Roy Cole Community Researcher, Team Trust
- Rupa Shree Appa-Pind Senior Project Lead, Novo Nordisk
- Russell Moul Science Writer, IFLScience
- Ruth Massey Professor, Ucc
- Ryan Nelson Field Application Scientist, Nuclera
- Saleha Patel Head Of Pipeline And Commercialisation Strategy, Constructive Bio
- Samantha Barichievy Senior Director Reagents & Assays Sweden, Astrazeneca
- Signe Vedel Borchert Preclinical Research Scientist, Calluna Pharma As
- Tammy Ladduwahetty Director, Medicinal Chemistry, Pharmaron
- Tim Ashlin Scientific Leader, GSK
- Vishal Sanchania Director of Pharmaceutical and Biotechnology Sciences, Cambridge Consultants - Part of Capgemini
- Wendy Winchester Senior Director, Nxera Pharma
- Yacine Dahman Ceo, Gris Noir
- Yann Abraham Head Of Drug Discovery, Deeplife
- Yanping Guo Flow Cytometry Facility Head, UCL Cancer Institute
Agenda
Showing 80 of 157 sessions.
- ELRIG Welcome - 20 years of community and inclusion - Del Trezise (ELRIG Chair) 14 October 2026 · Auditorium 1
- Conference Director Welcome & Keynote Introduction 14 October 2026 · Auditorium 1
- Plenary Keynote - Where Need Meets Momentum: The Next 20 Years - Sam Barrell 14 October 2026 · Auditorium 1
- Award presentation - ELRIG Outstanding Contribution Award 14 October 2026 · Auditorium 1
- Award presentation - ELRIG Innovation Award 14 October 2026 · Auditorium 1
- Breaking Through The Noise: Why Science Communication Is Important In A Distracted World - Russell Moul - IFL Science 14 October 2026 · Tech Theatre
- Panel session - Building your next chapter: Stories from beyond redundancy 14 October 2026 · Learning Zone
- From Attrition to Autonomy: Rearchitecting Scientific Intelligence for the Agentic AI Era - Justin Melnick 14 October 2026
- Track Chair - Targeted potency: Advances in radioligands and bioconjugates 14 October 2026 · Auditorium 3
- Track Chair - CRISPR/Cas technologies from discovery to therapeutic application 14 October 2026 · Tech Theatre
- Track Chair - Translating ideas into therapies - Navigating the challenges 14 October 2026 · Exhibition Hall Theatre
- Track Chair - Next-gen biophysics 14 October 2026 · Auditorium 4
- Track Chair - Integrating experimental design, lab-in-the-loop and AI towards translatable discovery 14 October 2026 · Auditorium 2
- Track Chair - Engineering the cell microenvironment: Cell-based models for drug discovery 14 October 2026 · Auditorium 1
- Breakthrough Zone - flash company presentations. 14 October 2026 · Breakthrough Zone
- The drugs are in the details: A microscopy-based CRISPR screen reveals unexpected vulnerabilities of a neglected parasitic disease- Bishara Marzook 14 October 2026 · Tech Theatre
- From Design Space to Data Space: An AI-Driven Approach to Better Cell Models and Smarter Assays - Samantha Barichievy 14 October 2026 · Auditorium 2
- Targeting the GI tract by design, from inception to the clinic - Wendy Winchester 14 October 2026 · Exhibition Hall Theatre
- Biodiversity at Scale - Ana Amélia Sanchez Iacia 14 October 2026 · Auditorium 1
- Biophysics: A Look Back at Changing Tools and Changing Questions - Chun-wa Chung 14 October 2026 · Auditorium 4
- Precision Guided Radiotherapeutics: Bicycle® Radionuclide Conjugates (BRC®) as next generation treatment options for solid tumours - Alonso Haysom-Rodriguez 14 October 2026 · Auditorium 3
- Conference Partner - WuXi App Tec UK Ltd - Integrated Discovery of Targeted Delivery Ligands for Oligonucleotide Therapeutics - Bin Liu 14 October 2026 · Auditorium 3
- Conference Partner - Nuclera - Closing the AI Antibody DBTL Loop with Cell-Free Screening - Ryan Nelson 14 October 2026 · Auditorium 2
- Conference Partner - Hamilton - Automating In Vivo Antibody Discovery - Ben Dugan 14 October 2026 · Exhibition Hall Theatre
- Industry Insider - SPT Labtech - An Integrated, High-Throughput Patient-Derived Organoid Platform for Long-Term Phenotypic Assays and Complex Cell-Based Drug Discovery - Dario De Felice 14 October 2026 · Auditorium 1
- Conference Partner - Carterra -HT-SPR Technology as a Data Engine for AI-Driven Drug Design - Daniel Bedinger 14 October 2026 · Auditorium 4
- Industry Insider - Evotec (Cyprotex) - A Transcriptomics‑AI Framework for Early Detection and De‑Risking of Nephrotoxicity - Nuno Santos Leal 14 October 2026 · Auditorium 1
- Finding Small Molecule Tools in Compound Pools using Surface Plasmon Resonance - Göran Dahl 14 October 2026 · Auditorium 4
- Optimising and Miniaturising Translational Assays to Enable AI-Driven Drug Discovery, Harnessing Modern Laboratory Automation and Design of Experiments - Sarah Martin 14 October 2026 · Auditorium 2
- Novel Therapeutic Targets in Cancer: Translating RAGE and Calpain Biology into Therapeutics, Biomarkers, and Patient Benefit - Danielle Harper 14 October 2026 · Auditorium 1
- Lonza’s GlycoConnect® Technology for Best-in-Class ADCs: Emerging Clinical Insights - Remon Van Geel 14 October 2026 · Auditorium 3
- Introns: From Nature to Design - Kärt Tomberg 14 October 2026 · Exhibition Hall Theatre
- Application of CRISPR screens for therapeutic target identification and validation in cancer drug discovery - Lovely Paul Solomon Devakumar 14 October 2026 · Tech Theatre
- Technology Spotlight - Partition Bio 14 October 2026 · Tech Theatre
- Technology Spotlight - Genedata 14 October 2026 · Auditorium 2
- Technology Spotlight - Maxcyte 14 October 2026 · Exhibition Hall Theatre
- Technology Spotlight - Bruker Biosensors 14 October 2026 · Auditorium 4
- Technology Spotlight - EditCo 14 October 2026 · Auditorium 1
- Endogenous Biology at Scale: HiBiT Knock-In for Challenging Targets at AI Drug Discovery Company Recursion- Promega Workshop 13.10-13.50 14 October 2026 · Breakthrough Zone
- Beyond the lab: Expanding biopharma R&D into new environments - Satellite Applications Catapult Showcase - 13.10 to 13.50 14 October 2026 · Tech Theatre
- Early Career Professional - Flash poster presentations 14 October 2026 · Learning Zone
- A CRISPR way to understand neurodegeneration - Andrew Bassett 14 October 2026 · Tech Theatre
- Designing Smarter Experiments: Connecting DoE, Laboratory Automation and AI in a Translational Discovery Workflow - Tim Ashlin 14 October 2026 · Auditorium 2
- Breakthrough Zone - flash company presentations 14 October 2026 · Breakthrough Zone
- Development of ADCs with enhanced therapeutic potential - Justyna Mysliwy 14 October 2026 · Auditorium 3
- Intratarget Microdosing in the human lung to accelerate therapeutic development - Kev Dhaliwal 14 October 2026 · Exhibition Hall Theatre
- Sarcoma patient derived 3D cell culture models for drug discovery and prediction of the clinical trials outcome- Juergen Loskutov 14 October 2026 · Auditorium 1
- In situ HDX-MS of membrane proteins for drug discovery - Argyris Politis 14 October 2026 · Auditorium 4
- Technology Spotlight - Cell Signaling 14 October 2026 · Auditorium 1
- Technology Spotlight - WuXi 14 October 2026 · Auditorium 3
- Technology Spotlight - Cube Biotech 14 October 2026 · Auditorium 4
- Technology Spotlight - Myllia 14 October 2026 · Tech Theatre
- Technology Spotlight - Domainex 14 October 2026 · Exhibition Hall Theatre
- Technology Spotlight - Instem 14 October 2026 · Auditorium 2
- Technology Spotlight - bit.bio 14 October 2026 · Auditorium 1
- Technology Spotlight - Anivance 14 October 2026 · Auditorium 2
- CRISPR screening in patient-derived intestinal organoids for inflammatory bowel disease target discovery at the FGSL - Antigoni Gogolou 14 October 2026 · Tech Theatre
- From Idea to Clinic: Lessons from Apollo - Darren Cawkill 14 October 2026 · Exhibition Hall Theatre
- Engineering end-to-end multi-modal workflows in 3D cell cultures - Olivier Frey 14 October 2026 · Auditorium 2
- In-cell NMR: a powerful approach for drug discovery - Lucia Banci 14 October 2026 · Auditorium 4
- Transforming Targeted Therapeutics: Innovation in ADC Bioconjugation and Radioligands - Balakumar Vijayakrishnan 14 October 2026 · Auditorium 3
- Patient-Derived Intestinal Organoids: Advancing Gut Complexity for Drug Discovery and Development - Andrea Gamir Morralla 14 October 2026 · Auditorium 1
- Panel - To PhD or not to PhD? Navigating Life Sciences careers as an ECP 14 October 2026 · Learning Zone
- Characterization of pre|CISION®-Peptide Drug Conjugates delivering single and dual cytotoxic payloads to the tumor microenvironment following FAP cleavage - Manuel Pinto 14 October 2026 · Auditorium 3
- Macrocyclic peptides achieving antibody-like potency and selectivity with oral delivery: A focus on biophysical techniques for highly potent compounds - Joshua Schwochert 14 October 2026 · Auditorium 4
- Therapeutic application of “ready-made” base-edited CAR T cells in leukaemia - Christos Georgiadis 14 October 2026 · Tech Theatre
- Decoding how immune receptors and extracellular vesicles build lymphocyte networks using synthetic cells, lymphoid organoids, and tumoroids - Pablo Cespedes 14 October 2026 · Auditorium 1
- Breakthrough Zone - flash company presentations 14 October 2026 · Breakthrough Zone
- Development of CAL101– a humanized monoclonal antibody targeting S100A4 to inhibit proinflammatory and profibrotic signaling in chronic fibrotic diseases - Signe Vedel Borchert 14 October 2026 · Exhibition Hall Theatre
- TwinCell: Large Causal Cell Model for Reliable and Interpretable Therapeutic Target Prioritisation - Yann Abraham 14 October 2026 · Auditorium 2
- Industry Insider - Evotec International GmbH -Biosensor based screening of large lead like chemical libraries in pools – an alternative biophysical approach for hit identification in small molecule drug discovery - Florian Krieger 14 October 2026 · Auditorium 4
- Industry Insider - Collaborative Drug Discovery Inc -AI-Ready Drug Discovery with CDD Vault: Why Your Scientific Data Strategy Matters When Defining Your AI Strategy - Antima Gupta 14 October 2026 · Auditorium 2
- Industry Insider - MDC - Advancing Drug Discovery Through Radiopharmaceutical Innovation 14 October 2026 · Auditorium 3
- Industry Insider - Promega UK Ltd - TarSeer™ BRETSA™ Target Engagement System – a sensitive, broadly applicable method to confirm target engagement through protein denaturation in cells - Craig Malcolm 14 October 2026 · Auditorium 1
- Industry Insider - Sartorius UK Ltd - From Molecule to Medicine: Navigating the Biosimilar Journey with Octet® BLI 14 October 2026 · Exhibition Hall Theatre
- Industry Insider - Trince - Photoporation Enables Plate-Based and Spatially Controlled CRISPR-Cas9 Gene Editing in Adherent Cell Models - Emilie Bureau 14 October 2026 · Tech Theatre
- Panel Session - Invitro Models- the future 14 October 2026 · Auditorium 1
- The pharmacology of orforglipron, an orally bioavailable, non-peptide agonist of the GLP-1 receptor - Matthew Coghlan 14 October 2026 · Exhibition Hall Theatre
- Rewriting Disease-Causing Variants: Templated Editing In Vivo - Marcello Maresca 14 October 2026 · Tech Theatre
- Combining high throughput native MS screening with synthetic biology to target intricate proteins - Idi Liko 14 October 2026 · Auditorium 4